I must say that in the VEXAS realm I’m mostly excited because now we have a trial that we are running and it’s with pacritinib, it’s the PAXIS trial. I’m very happy to have four patients enrolled currently and now the enrollment has been paused due to the first 30 patients reaching the number that is needed for the interim analysis of safety...
I must say that in the VEXAS realm I’m mostly excited because now we have a trial that we are running and it’s with pacritinib, it’s the PAXIS trial. I’m very happy to have four patients enrolled currently and now the enrollment has been paused due to the first 30 patients reaching the number that is needed for the interim analysis of safety. And therefore, we are waiting to add more patients. I mean, this is, I think, like a big opportunity and a big breakthrough in the field. If we think that like five years ago, we didn’t know what VEXAS was and now we are enrolling patients to a trial. I think this is what excites us all when we are here at ASH. So I think that in the VEXAS realm now, we know a lot about the biology of the disease. We now need to focus on how to treat our patients best and a clinical trial is the way to go.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
